Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid

M. Marra, D. Santini, G. Tonini, G. Meo, S. Zappavigna, G. Facchini, A. Morabito, A. Abbruzzese, G. Cartenì, A. Budillon, M. Caraglia

Research output: Contribution to journalArticlepeer-review


Zoledronic acid (ZOL) is an aminobisphosphonate able to inhibit the prenylation of intracellular proteins through the inhibition of farnesylpyrophosphate synthase. Prenylation is essential for the maintenance of the activation of components of signal transduction pathways regulating apoptosis and proliferation such as Ras and Ras-related proteins. ZOL has demonstrated a direct anti-tumour effect in vitro and in preclinical models, and its ability in preventing skeletal-related events is proven in patients with bone metastases from different origins. Clinical evidence on its direct anti-proliferative effects is emerging. We describe several strategies in order to improve the anti-tumour activity of ZOL. In detail, we illustrate new combinations between ZOL and cytotoxic drugs or other biological agents such as the farnesyltransferase inhibitor tipifarnib focusing on the sequence of administration of these drugs. Moreover, the efforts to find new molecular targets of ZOL through the use of technological platforms such as DNA microarrays are described.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalEuropean Journal of Cancer, Supplement
Issue number14
Publication statusPublished - Oct 2008


  • Aminobisphosphonates
  • Breast cancer
  • Clinical activity
  • Cyr61
  • Docetaxel
  • Farnesyltransferase inhibitors
  • Invasion
  • Microarray
  • Prostate cancer
  • Zoledronic acid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid'. Together they form a unique fingerprint.

Cite this